NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2025. SO WHAT: If you purchased Actinium securi ...

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Mullen Automotive, Inc. f/k/a Net Element, Inc. (NASDAQ: MULN, NETE) between February 3, 2023 and March 13, 2024, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Mullen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs throu ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any o ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), of the important May 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Civitas Resources, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Class Action - Shareholders of Civitas Resources may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - Investors can join the prospective class action by submitting a form or contacting the law firm directly [2]. Group 2: Financial Performance and Impact - On February 24, 2025, Civitas Resources reported earnings that missed estimates by $0.16, with quarterly revenue of $1.29 billion, falling short of the consensus estimate of $1.3 billion [3]. - Following the earnings report, Civitas announced the termination of its chief operating officer and chief transformation officer, which contributed to an 18% drop in the stock price on February 25, 2025 [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized as a leader in the field [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5].

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for alleged misleading statements regarding its Iomab-B Biologics License Application during the Class Period from October 31, 2022, to August 2, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Actinium made false statements and failed to disclose critical information about the likelihood of FDA approval for its Iomab-B BLA [5]. - Specific allegations include that data from the Sierra Trial was unlikely to meet FDA guidelines, and additional analyses provided to the FDA were also unlikely to satisfy approval requirements [5]. - As a result of these misleading statements, investors reportedly suffered damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased Actinium securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Atkore Inc. (NYSE: ATKR) between August 2, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased Atkore common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FMC Corporation (NYSE: FMC) between November 16, 2023 and February 4, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased FMC securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Ready Capital common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Target Corporation common stock between August 26, 2022, and November 19, 2024, of the April 1, 2025, deadline to become a lead plaintiff in a class action lawsuit related to misleading statements made by Target regarding its ESG and DEI initiatives [1][4]. Group 1: Class Action Details - Investors who bought Target stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][6]. - The deadline to move the Court to serve as lead plaintiff is April 1, 2025, with the lead plaintiff acting on behalf of other class members [2]. Group 2: Allegations Against Target - The lawsuit claims that Target misled investors with false statements about its ESG and DEI mandates, which led to customer boycotts following the 2023 LGBT-Pride Campaign [4]. - The negative impact of the Campaign resulted in a decline in Target's stock price and sales falling for the first time in six years [5]. - It is alleged that Target's CEO and Board did not disclose known risks associated with the 2023 and 2024 Campaigns, leading to investors purchasing stock at artificially inflated prices [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].